Home / PDSB : NASDAQ

AI Analysis Fundamentals Valuation Video Analysis News Similar

AI Analysis

How does PDSB make money? Does PDSB have pricing power? What's the Earnings Whisper? Will PDSB profit more as the business scales? What is PDSB's management track record? Is PDSB's current price justified?

PDS Biotechnology Corporation

$0.29 -$0.54 (-64.61%)

NASDAQ · 11 Sep 2026 20:00 UTC

Previous Close

$0.32

Day Range

$0.29$0.32

Year Range

$0.2$1.55

Market Cap

16.49M

AVG Volume

6.87M

Trailing/Forward PE

-0.46/-

PEG ratio

0.01

Dividend Yield

Next Earnings Date

2026-11-12

Primary Exchange

NASDAQ

Net Income (USD)

PDSB Net Income (USD) by quarter
Period	Net Income (USD)
26 Q2	-9.75M
26 Q1	-7.35M
25 Q4	-7.56M
25 Q3	-9.01M
25 Q2	-9.43M
25 Q1	-8.49M
24 Q4	-7.95M
24 Q3	-10.73M
24 Q2	-8.33M
24 Q1	-10.6M

Operating Income (USD)

PDSB Operating Income (USD) by quarter
Period	Operating Income (USD)
26 Q2	-6.5M
26 Q1	-6.52M
25 Q4	-6.67M
25 Q3	-8.14M
25 Q2	-7.62M
25 Q1	-9.11M
24 Q4	-7.36M
24 Q3	-10.18M
24 Q2	-8.68M
24 Q1	-10.1M

EBITDA (USD)

PDSB EBITDA (USD) by quarter
Period	EBITDA (USD)
26 Q2	-6.5M
26 Q1	-6.33M
25 Q4	-6.44M
25 Q3	-7.85M
25 Q2	-7.28M
25 Q1	-8.72M
24 Q4	-6.84M
24 Q3	-9.51M
24 Q2	-8M
24 Q1	-9.42M

Cash Flows (USD)

PDSB Cash Flows (USD) by quarter
Period	Cash Flows (USD)
26 Q2	-2.79M
26 Q1	-4.37M
25 Q4	-3.7M
25 Q3	-5.92M
25 Q2	-9.1M
25 Q1	-9.03M
24 Q4	-8.23M
24 Q3	-8M
24 Q2	-8.89M
24 Q1	-9.94M

EPS (USD)

PDSB EPS (USD) by quarter
Period	EPS (USD)
26 Q2	-0.18
26 Q1	-0.13
25 Q4	-0.14
25 Q3	-0.19
25 Q2	-0.21
25 Q1	-0.21
24 Q4	-0.22
24 Q3	-0.29
24 Q2	-0.23
24 Q1	-0.3

Expenses (USD)

PDSB Expenses (USD) by quarter
Period	Expenses (USD)
26 Q2	6.5M
26 Q1	3.07B
25 Q4	6.67M
25 Q3	8.14M
25 Q2	7.62M
25 Q1	9.11M
24 Q4	7.35M
24 Q3	10.18M
24 Q2	8.71M
24 Q1	10.1M

Cash & Debt (USD)

PDSB Cash & Debt (USD) by quarter
Period	Cash & Debt (USD)
26 Q2	5.6M
26 Q1	21.66M
25 Q4	26.71M
25 Q3	26.2M
25 Q2	31.87M
25 Q1	39.98M
24 Q4	41.69M
24 Q3	49.75M
24 Q2	57.73M
24 Q1	66.63M

Debt ratios

PDSB Debt ratios by quarter
Period	Debt ratios
26 Q2	0.05
26 Q1	0.21
25 Q4	0.32
25 Q3	0.27
25 Q2	0.41
25 Q1	0.64
24 Q4	0.59
24 Q3	0.68
24 Q2	0.9
24 Q1	1.04

Return on Capital

PDSB Return on Capital by quarter
Period	Return on Capital
26 Q2	272.38%
26 Q1	-188.79%
25 Q4	-81.75%
25 Q3	-95.3%
25 Q2	-59.11%
25 Q1	-37.96%
24 Q4	-41.84%
24 Q3	-48.76%
24 Q2	-26.94%
24 Q1	-28.52%

Shares Outstanding

PDSB Shares Outstanding by quarter
Period	Shares Outstanding
26 Q2	55.66M
26 Q1	55.5M
25 Q4	46.38M
25 Q3	46.87M
25 Q2	45.9M
25 Q1	40.52M
24 Q4	36.45M
24 Q3	36.81M
24 Q2	36.69M
24 Q1	34.82M

Book Value Per Share (USD)

PDSB Book Value Per Share (USD) by quarter
Period	Book Value Per Share (USD)
26 Q2	-0.06
26 Q1	0.07
25 Q4	0.2
25 Q3	0.2
25 Q2	0.35
25 Q1	0.55
24 Q4	0.52
24 Q3	0.6
24 Q2	0.84
24 Q1	1.07

Total Assets (USD)

PDSB Total Assets (USD) by quarter
Period	Total Assets (USD)
26 Q2	8.81M
26 Q1	24.66M
25 Q4	30.49M
25 Q3	34.71M
25 Q2	40.48M
25 Q1	47.03M
24 Q4	45.36M
24 Q3	52.45M
24 Q2	60.5M
24 Q1	69.01M

Employee Count

PDSB Employee Count by quarter
Period	Employee Count
2025	21
2024	24
2023	25
2022	26
2021	22
2020	15
2019	15
2018	10
2017	38
2016	31

Free Cash Flow Yield

PDSB Free Cash Flow Yield by quarter
Period	Free Cash Flow Yield
Sep 26	-102.25%
Sep 26	-137.06%
Aug 26	-142.97%
Aug 26	-138%
Aug 26	-130.76%
Aug 26	-53.67%
Jul 26	-60.65%
Jul 26	-61.06%
Jul 26	-56.62%
Jul 26	-53.77%
Jul 26	-48.77%
Jun 26	-46.83%
Jun 26	-43.57%
Jun 26	-39.63%
Jun 26	-40.79%
May 26	-38.53%
May 26	-34.67%
May 26	-31.05%
May 26	-47.86%
May 26	-61.01%
Apr 26	-66.44%
Apr 26	-45.67%
Apr 26	-55.4%
Apr 26	-94.22%
Mar 26	-127.23%
Mar 26	-120.63%
Mar 26	-109.16%
Mar 26	-102.36%
Feb 26	-102.04%
Feb 26	-106.3%
Feb 26	-98.29%
Feb 26	-96.34%
Jan 26	-82.71%
Jan 26	-72.51%
Jan 26	-72.41%
Jan 26	-64.37%
Jan 26	-82.67%
Dec 25	-76.18%
Dec 25	-77.38%
Dec 25	-70.71%
Dec 25	-79.17%
Nov 25	-89.34%
Nov 25	-91.18%
Nov 25	-81.95%
Nov 25	-82.22%
Oct 25	-80.07%
Oct 25	-81.42%
Oct 25	-80.83%
Oct 25	-79.04%
Oct 25	-73.4%
Sep 25	-73.4%
Sep 25	-71.31%
Sep 25	-64.54%
Sep 25	-62.39%
Aug 25	-60.38%
Aug 25	-62.92%
Aug 25	-62.92%
Aug 25	-75.93%
Aug 25	-77.33%
Jul 25	-71.43%
Jul 25	-73.29%
Jul 25	-67.97%
Jul 25	-63.37%
Jun 25	-59.78%
Jun 25	-52.03%
Jun 25	-48.16%
Jun 25	-49.87%
May 25	-61.08%
May 25	-53.35%
May 25	-59.36%
May 25	-80.15%
May 25	-69.69%
Apr 25	-76.94%
Apr 25	-89.05%
Apr 25	-93.38%
Apr 25	-101.23%
Mar 25	-76.33%
Mar 25	-69.97%
Mar 25	-77.93%
Mar 25	-77.93%
Feb 25	-72.07%
Feb 25	-71.53%
Feb 25	-61.45%
Feb 25	-65.66%
Jan 25	-58.45%
Jan 25	-61.84%
Jan 25	-66.11%
Jan 25	-67.98%
Jan 25	-53.25%
Dec 24	-56.06%
Dec 24	-58.09%
Dec 24	-52.1%
Dec 24	-44.17%
Nov 24	-43.77%
Nov 24	-45.86%
Nov 24	-47.69%
Nov 24	-28.54%
Nov 24	-29.35%
Oct 24	-30.1%
Oct 24	-28.89%

Price to Book

PDSB Price to Book by quarter
Period	Price to Book
Aug 26	11.05
Jul 26	9.78
Jul 26	9.71
Jul 26	10.48
Jul 26	11.03
Jul 26	12.16
Jun 26	12.67
Jun 26	13.62
Jun 26	14.97
Jun 26	14.54
May 26	15.4
May 26	17.11
May 26	19.1
May 26	6.27
May 26	4.92
Apr 26	4.51
Apr 26	6.57
Apr 26	5.41
Apr 26	3.18
Mar 26	2.68
Mar 26	2.83
Mar 26	3.13
Mar 26	3.34
Feb 26	3.35
Feb 26	3.21
Feb 26	3.47
Feb 26	3.54
Jan 26	4.13
Jan 26	4.71
Jan 26	4.72
Jan 26	5.3
Jan 26	4.13
Dec 25	4.48
Dec 25	4.41
Dec 25	4.83
Dec 25	4.31
Nov 25	3.82
Nov 25	3.75
Nov 25	4.17
Nov 25	2.62
Oct 25	2.69
Oct 25	2.64
Oct 25	2.66
Oct 25	2.72
Oct 25	2.93
Sep 25	2.93
Sep 25	3.02
Sep 25	3.34
Sep 25	3.45
Aug 25	3.57
Aug 25	3.42
Aug 25	3.42
Aug 25	2.01
Aug 25	1.98
Jul 25	2.14
Jul 25	2.08
Jul 25	2.25
Jul 25	2.41
Jun 25	2.55
Jun 25	2.94
Jun 25	3.17
Jun 25	3.06
May 25	2.5
May 25	2.86
May 25	2.57
May 25	2.3
May 25	2.65
Apr 25	2.4
Apr 25	2.07
Apr 25	1.98
Apr 25	1.82
Mar 25	2.42
Mar 25	2.29
Mar 25	2.06
Mar 25	2.06
Feb 25	2.23
Feb 25	2.24
Feb 25	2.61
Feb 25	2.44
Jan 25	2.74
Jan 25	2.59
Jan 25	2.43
Jan 25	2.36
Jan 25	3.01
Dec 24	2.86
Dec 24	2.76
Dec 24	3.08
Dec 24	3.63
Nov 24	3.66
Nov 24	3.5
Nov 24	3.36
Nov 24	3.9
Nov 24	3.8
Oct 24	3.7
Oct 24	3.86
Oct 24	4.06
Oct 24	4.4
Sep 24	4
Sep 24	3.8
Sep 24	3.56

No video analysis for this stock yet. Request one from our team.

News: PDSB

defenseworld.net · 9 Sep 2026

Traders Buy Large Volume of Call Options on PDS Biotechnology (NASDAQ:PDSB)

PDS Biotechnology Corporation (NASDAQ: PDSB - Get Free Report) was the target of some unusual options trading activity on Tuesday. Investors acquired 1,957 call options on the stock. This represents an increase of 1,154% compared to the average daily volume of 156 call options. Analyst Upgrades and Downgrades Several research firms recently issued reports on PDSB.

globenewswire.com · 8 Sep 2026

PDS Biotech Announces up to $22.55 Million Financing Led by Dr. Patrick Soon-Shiong, Founder of NantWorks

Dr. Soon-Shiong will Join PDS Biotech's Board of Directors PDS Biotech Plans to Progress Development of PDS0301 Immunocytokine in Solid Tumors PRINCETON, N.J., Sept. 08, 2026 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) ("PDS Biotech" or the "Company"), a clinical-stage biotechnology company focused on developing targeted immunotherapies for cancer, today announced it has raised up to $22.55 million in equity funding in a Private Investment in Public Equity (“PIPE”) transaction.

globenewswire.com · 13 Aug 2026

PDS Biotech Reports Second Quarter 2026 Financial Results

PRINCETON, N.J., Aug. 13, 2026 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a clinical-stage biotechnology company focused on developing targeted immunotherapies for cancer, today provided a business and clinical programs update and reported financial results for the quarter ended June 30, 2026.

benzinga.com · 11 Aug 2026

PDS Biotechnology Stock Crashes, Strategic Refocus Pivots to Metastatic Colorectal Cancer Program

PDS Biotechnology Corporation (NASDAQ:PDSB) shares have fallen by about 67% on Tuesday as the company announced a strategic refocus on its PDS0301 program for metastatic colorectal cancer.

globenewswire.com · 11 Aug 2026

PDS Biotech Announces Strategic Refocus Prioritizing PDS0301 in Metastatic Colorectal Cancer (mCRC) and Partnership Strategy for PDS0101

PRINCETON, N.J., Aug. 11, 2026 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on developing targeted immunotherapies for cancer, today issued a Letter to Shareholders from Frank Bedu-Addo, Ph.D.